Insider · CIK 0001191713
Shellye L Archambeau
director
Files at VZ (VERIZON COMMUNICATIONS INC), ROP (ROPER TECHNOLOGIES INC), OKTA (Okta, Inc.), LINE (Lineage, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | ROP ROPER TECHNOLOGIES INC | AGrant or award Common Stock | +84 | $0.00 | $0 | 9,561 | 25 d ago |
| Sep 15, 2025 | ROP ROPER TECHNOLOGIES INC | AGrant or award Common Stock | +64 | $0.00 | $0 | 8,194 | Sep 17, 2025 |
| Jun 20, 2025 | OKTA Okta, Inc. | MOption exercise Class A Common Stock | +2,832 | $0.00 | $0 | 11,692 | Jun 24, 2025 |
| Jun 20, 2025 | OKTA Okta, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,832 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 24, 2025 | OKTA Okta, Inc. | AGrant or award Restricted Stock Unitsderivative | +2,487 | $0.00 | $0 | 2,487 | Jun 24, 2025 |
| Jun 18, 2025 | LINE Lineage, Inc. | AGrant or award Common Stock | +4,490 | $0.00 | $0 | 7,622 | Jun 20, 2025 |
| Jun 11, 2025 | ROP ROPER TECHNOLOGIES INC | AGrant or award Common Stock | +675 | $0.00 | $0 | 8,130 | Jun 13, 2025 |
| Mar 18, 2025 | VZ VERIZON COMMUNICATIONS INC | AGrant or award Phantom Stockderivativeindirect: By Deferred Compensation Plan | +4,748 | $0.00 | $0 | 64,596 | Mar 20, 2025 |
| Nov 26, 2024 | ROP ROPER TECHNOLOGIES INC | GGift Common Stock | -625 | $0.00 | $0 | 7,455 | Nov 27, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.